Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer

Breast Cancer Research

Volumn 14, Issue 5, 2012, Pages

  Switzer, Christopher H ^a   Cheng, Robert Y S ^a   Ridnour, Lisa A ^a   Glynn, Sharon A ^a,b   Ambs, Stefan ^a   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA CRYSTALLIN; CALGRANULIN A; CATHEPSIN B; COLLAGENASE 3; DIETHLYLENETRIAMINE NONOATE; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTROPHIL COLLAGENASE; NITRIC OXIDE DONOR; P CADHERIN; RAS PROTEIN; STROMELYSIN; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NOS2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NITROSYLATION; ONCOGENE; PHENOTYPE; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; PROTO-ONCOGENE PROTEIN C-ETS-1; RAS PROTEINS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84866022996     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3319     Document Type: Article

References (60)

1. Wink DA, Hines HB, Cheng RYS, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 2011, 89:873-891. 10.1189/jlb.1010550, 3100761, 21233414.
2. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011, 146:53-66. 10.1016/j.cell.2011.06.006, 3144745, 21729780.
3. Cheng R, Ridnour LA, Glynn SA, Switzer CH, Flores-Santana W, Hussain P, Thomas DD, Ambs S, Harris CC, Wink DA. Nitric Oxide and Cancer: An Overview. Nitric Oxide (NO) and Cancer 2010, 3-20. New York: Springer, Bonavida B.
4. Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 2005, 5:103-115. 10.2174/1568009053202072, 15810875.
5. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010, 120:3843-3854. 10.1172/JCI42059, 2964971, 20978357.
6. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
7. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26:2568-2581. 10.1200/JCO.2007.13.1748, 18487574.
8. Switzer CH, Glynn SA, Ridnour LA, Cheng RYS, Vitek MP, Ambs S, Wink DA. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci 2011, 32:644-651. 10.1016/j.tips.2011.07.001, 3380363, 21893353.
9. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008, 45:18-31. 10.1016/j.freeradbiomed.2008.03.020, 2572721, 18439435.
10. Pervin S, Chaudhuri G, Singh R. NO to breast: when, why and why not?. Curr Pharm Des 2010, 16:451-462. 10.2174/138161210790232130, 20236074.
11. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534. 10.1038/nrc1910, 16794635.
12. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007, 120:796-805. 10.1002/ijc.22336, 17096325.
13. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA. Hypoxic inducible factor 1a, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004, 101:8894-8899. 10.1073/pnas.0400453101, 428443, 15178764.
14. Rahman MA, Senga T, Ito S, Hyodo T, Hasegawa H, Hamaguchi M. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem 2010, 285:3806-3814. 10.1074/jbc.M109.059782, 2823522, 19948721.
15. Lee H-C, An S, Lee H, Woo S-H, Jin H-O, Seo S-K, Choe T-B, Yoo D-H, Lee S-J, Hong Y-J, Park M-J, Rhee C-H, Park I-C, Hong S-I. Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. Mol Cancer Res 2008, 6:996-1002. 10.1158/1541-7786.MCR-08-0113, 18567803.
16. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 2005, 24:5384-5388. 10.1038/sj.onc.1208761, 15940256.
17. Furlan A, Vercamer C, Desbiens X, Pourtier A. Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J Cell Physiol 2008, 215:782-793. 10.1002/jcp.21360, 18181172.
18. Turner DP, Findlay VJ, Moussa O, Watson DK. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem 2007, 102:549-559. 10.1002/jcb.21494, 17661355.
19. Mylona EE, Alexandrou PT, Giannopoulou IA, Rafailidis PI, Markaki S, Keramopoulos A, Nakopoulou LL. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype. Cancer Detect Prev 2006, 30:111-117. 10.1016/j.cdp.2006.03.006, 16632244.
20. Lincoln DW 2, Bove K. The transcription factor Ets-1 in breast cancer. Front Biosci 2005, 10:506-511. 10.2741/1546, 15574387.
21. Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O'Higgins N, Duffy MJ. Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 2004, 91:1308-1315. 10.1038/sj.bjc.6602128, 2409905, 15365563.
22. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002, 21:8506-8509. 10.1038/sj.onc.1206040, 12466970.
23. Bosman JD, Yehiely F, Evans JR, Cryns VL. Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer. Breast Cancer Res Treat 2010, 119:63-70. 10.1007/s10549-009-0330-4, 2791186, 19205872.
24. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, Stacey KJ, Hume DA, Maki RA, Ostrowski MC. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 1996, 16:538-547. 231032, 8552081.
25. Wasylyk C, Bradford AP, Gutierrez-Hartmann A, Wasylyk B. Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene 1997, 14:899-913. 10.1038/sj.onc.1200914, 9050989.
26. Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, Vandenbunder B, Fafeur V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 2002, 21:2309-2319. 10.1038/sj.onc.1205297, 11948414.
27. Iwasaka C, Tanaka K, Abe M, Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996, 169:522-531. 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.0.CO;2-7, 8952701.
28. Chen Z, Fisher RJ, Riggs CW, Rhim JS, Lautenberger JA. Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res 1997, 57:2013-2019.
29. Sahin A, Velten M, Pietsch T, Knuefermann P, Okuducu AF, Hahne JC, Wernert N. Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med 2005, 15:771-776.
30. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA 2007, 104:16898-16903. 10.1073/pnas.0702761104, 2040425, 17942699.
31. Keefer LK, Nims RW, Davies KM, Wink DA. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 1996, 268:281-293.
32. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351:289-305. 10.1042/0264-6021:3510289, 1221363, 11023813.
33. Lander HM, Hajjar DP, Hempstead BL, Mirza UA, Chait BT, Campbell S, Quilliam LA. A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. J Biol Chem 1997, 272:4323-4326. 10.1074/jbc.272.7.4323, 9020151.
34. Mirza UA, Chait BT, Lander HM. Monitoring reactions of nitric oxide with peptides and proteins by electrospray ionization-mass spectrometry. J Biol Chem 1995, 270:17185-17188. 10.1074/jbc.270.29.17185, 7615515.
35. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001, 2001:pl1.
36. Wink DA, Nims RW, Darbyshire JF, Christodoulou D, Hanbauer I, Cox GW, Laval F, Laval J, Cook JA, Krishna MC. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol 1994, 7:519-525. 10.1021/tx00040a007, 7981416.
37. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. Dislodgment and accelerated degradation of Ras. Biochemistry 1998, 37:1306-1314. 10.1021/bi972032d, 9477957.
38. Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, Dittmer J. Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol 2003, 22:799-805.
39. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR. Protein kinase C[alpha] activates RAF-1 by direct phosphorylation. Nature 1993, 364:249-252. 10.1038/364249a0, 8321321.
40. Vetter M, Blumenthal SG, Lindemann RK, Manns J, Wesselborg S, Thomssen C, Dittmer J. Ets1 is an effector of protein kinase C[alpha] in cancer cells. Oncogene 2005, 24:650-661. 10.1038/sj.onc.1208234, 15531915.
41. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003, 2:29. 10.1186/1476-4598-2-29, 194255, 12971829.
42. Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001, 194:43-50. 10.1002/path.844, 11329140.
43. Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 2001, 101:242-247. 10.1006/jsre.2001.6279, 11735282.
44. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257. 10.1186/bcr65, 138784, 11250717.
45. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale A-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
46. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284. 10.1038/sj.onc.1209254, 16288205.
47. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011, 13:R97. 10.1186/bcr3035, 3262210, 21978456.
48. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol 2008, 12:33-40. 10.1016/j.anndiagpath.2007.02.004, 18164413.
49. Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012, 72:1199-1209. 10.1158/0008-5472.CAN-11-2759, 22266111.
50. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005, 52:1-9. 10.2152/jmi.52.1, 15751268.
51. Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD, Wink DA. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008, 19:73-76. 10.1016/j.niox.2008.04.006, 2574989, 18472020.
52. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000, 62:51-62. 10.1023/A:1006491619920, 10989985.
53. Sanchez-Munoz A, Gallego E, de Luque V, Perez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 2010, 10:136. 10.1186/1471-2407-10-136, 2868051, 20385028.
54. Deora AA, Hajjar DP, Lander HM. Recruitment and activation of Raf-1 kinase by nitric oxide-activated Ras. Biochemistry 2000, 39:9901-9908. 10.1021/bi992954b, 10933809.
55. Marozkina NV, Wei C, Yemen S, Wallrabe H, Nagji AS, Liu L, Morozkina T, Jones DR, Gaston B. S-Nitrosoglutathione reductase in human lung cancer. Am J Respir Cell Mol Biol 2012, 46:63-70. 10.1165/rcmb.2011-0147OC, 21816964.
56. Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 2007, 67:289-299. 10.1158/0008-5472.CAN-05-4623, 17210710.
57. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000, 6:4768-4775.
58. Wei W, Li B, Hanes MA, Kakar S, Chen X, Liu L. S-Nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med 2:19ra13.
59. Yamaguchi E, Nakayama T, Nanashima A, Matsumoto K, Yasutake T, Sekine I, Nagayasu T. Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. Tohoku J Exp Med 2007, 213:41-50. 10.1620/tjem.213.41, 17785952.
60. Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 2004, 61:118-128. 10.1007/s00018-003-3337-8, 14704859.